Will stem cells eventually work? maybe but it is way too early to tell and not sure anyone is quit there yet. I would suggest you put your money where you mouth is and purchase NBS before they release trial results in the near future (be prepared to lose about 60-70% of your investment overnight.) My bet is on the short side but lets see who is right
New data reported by the Cardiovascular Cell Therapy Research Network (CCTRN) at the 2013 Scientific Sessions of the American Heart Association in Dallas showed that the use of bone marrow mononuclear stem cells (BMCs) did not improve heart function significantly more at one year than at six months. While there was measurable decrease in the size of scar tissue at six and 12 months, stem cells administered as a part of the TIME (Transplantation In Myocardial Infarction Evaluation) study did not improve overall heart functionality. The results were presented by Jay Traverse, MD of the Minneapolis Heart Institute Foundation on Nov. 18, 2013.
Background—Several cell-based therapies for adjunctive treatment of acute myocardial infarction have been investigated in multiple clinical trials, but the benefits still remain controversial. This meta-analysis aims to evaluate the efficacy of bone marrow–derived mononuclear cell (BMMNC) therapy in patients with acute myocardial infarction, but also explores the effect of newer generations of stem cells.
Methods and Results—A random-effects meta-analysis was performed on randomized controlled trials investigating the effects of stem cell therapy in patients with acute myocardial infarction that were published between January 2002 and September 2013. The defined end points were left ventricular (LV) ejection fraction, LV end-systolic and end-diastolic volumes, infarct size, and major adverse cardiac and cerebrovascular event rates. Also, several subgroup analyses were performed on BMMNC trials. Overall, combining the results of 22 randomized controlled trials (RCTs), LV ejection fraction increased by +2.10% (95% confidence interval [CI], 0.68–3.52; P=0.004) in the BMMNC group as compared with controls, evoked by a preservation of LV end-systolic volume (−4.05 mL; 95% CI, −6.91 to −1.18; P=0.006) and a reduction in infarct size (−2.69%; 95% CI, −4.83 to −0.56; P=0.01). However, there is no effect on cardiac function, volumes, or infarct size, when only RCTs (n=9) that used MRI-derived end points were analyzed. Moreover, no beneficial effect could be detected on major adverse cardiac and cerebrovascular event rates after BMMNC infusion after a median follow-up duration of 6 months.
Conclusions—Intracoronary infusion of BMMNC is safe, but does not enhance cardiac function on MRI-derived parameters, nor does it improve clinical outcome
Intracoronary Injection of Bone Marrow Derived Mononuclear Cells, Early or Late after Acute Myocardial Infarction: Effects on Global Left Ventricular Function Four months results of the SWISS-AMI trial
Background—Intracoronary administration of autologous bone marrow derived mononuclear cells (BM-MNC) may improve remodeling of the left ventricle (LV) after acute myocardial infarction (AMI). The optimal time point of administration of BM-MNC is still uncertain and has rarely been addressed prospectively in randomized clinical trials.
Methods and Results—In a multi-centre study, we randomized 200 patients with large, successfully reperfused ST segment elevation myocardial infarction (STEMI) in a 1:1:1 pattern into an open-labeled control and two BM-MNC treatment groups. In the BM-MNC groups cells were either administered "early", i.e. 5-7 days, or "late", i.e. 3-4 weeks after AMI. Cardiac magnetic resonance imaging was performed at baseline and after 4 months. The primary endpoint was the change from baseline to 4 months in global LV ejection fraction (LVEF) between the two treatment groups and the control group. The absolute change in LVEF from baseline to 4 months was -0.4±8.8% (mean±SD; p= 0.74 vs. baseline) in the control group, 1.8±8.4% (p = 0.12 vs. baseline) in the early group and 0.8±7.6% (p = 0.45 vs. baseline) in the late group. The treatment effect of BM-MNC as estimated by ANCOVA was 1.25 (95% CI -1.83 to 4.32; p = 0.42) for the early and 0.55 (95% CI -2.61 to 3.71; p = 0.73) for the late therapy group.
Conclusions—Among patients with STEMI and LV dysfunction following successful reperfusion, intracoronary infusion of BM-MNC either at 5-7 days or 3-4 weeks after AMI, did not improve LV-function at 4 months follow-up.
Obviously your trying to spread fear and that fine if that is your prerogative but at least take the time to share information that somehow remotely relates to SSH and its future. Trying to get people to sell because of new ISIS stronghold is as dumb and crazy as someone living with 11 cats. Now lets quit being lazy and come up with some better scare tactics. I want at least 10 of them today. Also you are not answering my question, how much money have you lost this year??
Yep he is the type of investor that will always lose money. When you are that confused you will make a lot of mistakes and will be broke soon
This is what AF has to say about it
On Neostem, the main stock value driver is AMR-001, an autologous stem cell therapy derived from a patient's bone marrow. Neostem believes these stem cells have healing properties, so when they're injected back into a patient who has suffered a heart attack, for example, AMR-011 will restore blood flow, rebuild the damaged cardiac muscle and improve function.
Autologous means the stem cells are harvested from, and re-injected into, the same individual, meaning AMR-001 must be manufactured specifically for each patient. This is not an off-the-shelf drug.
Neostem recently wrapped up enrollment in a double-blind, placebo controlled phase II study of AMR-001 in 160 patients following a heart attack. The primary endpoint of the study is to determine if AMR-001 improves blood flow through the heart, measured via a non-invasive imaging scan done after six months. Secondarily, the study will look at AMR-001's effect on other measures of cardiac function and post-treatment reductions in major adverse cardiac events (MACE) at 6, 12, 18, 24 and 36 months.
The first results from the AMR-001 "PreSERVE" study are expected in the third quarter, according to Neostem. The study was supposed to have completed and reported data before the end of 2013, but slow patient enrollment caused a significant delay.
Why is Neostem having trouble completing the AMR-001 phase II study? Perhaps because lots of trials injecting heart attack and heart disease patients with stem cells have already been conducted, producing mediocre results.
This past spring, Swiss researchers who injected bone marrow-derived stem cells into heart attack patients found no improvement in heart function.
Last April, the American Journal of Cardiology reported on a meta-analysis of 10 clinical trials involving stem-cell therapy in heart disease patients, which found improvements in some measures of heart function but no meaningful, positive impact on patients' lives.
In February 2014 we completed enrollment in the Phase 2b study with MYDICAR. This trial, "Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease" (the "CUPID 2 Trial") is a multinational, multicenter, double-blind, placebo-controlled, randomized study comparing a single intracoronary administration of MYDICAR versus placebo added to an optimal heart failure regimen. The primary objective is to determine the efficacy of MYDICAR in patients with ischemic or dilated cardiomyopathy and NYHA class III/IV symptoms of heart failure by reducing the frequency and/or delaying heart failure-related hospitalizations compared to placebo-treated patients. Secondary objectives include assessment of the safety of MYDICAR by determining the incidence and severity of adverse events and changes in laboratory parameters. A total of 250 patients were enrolled and data from this trial is expected in April 2015.
Im pretty sure English is his second language.
No he is not short. He is just a lonely guy that lacks any other social interaction other than this board. Poor guy is trying to convince himself that he is making the right investment decisions. The guy is never going to make a buck in the stock market.
Cutting edge? Their trial has been going on for 10 years and the technology is older than that. There is a reason why big pharma dropped this approach long ago. Longs need to stop working about AF, naked shorting, hedgies manipulation, etc.. and start concentrating on the science. There you will find the answer to whether you will be broke or rich someday. I would be interested if this approach if it was paired with the new class of immunotherapy drugs (Immune-checkpoint inhibitors). Unfortunately it is not and this drug is doomed. Wall street knows this how there is obviously a lot of retail investors do not
Yeah the shorts get nervous so you start to see a lot of the "sky is falling" comments show up. Maybe venting some of their frustration on this message board helps ease their pain of the $$$ eroding away.
Why the heck would you have covered after the latest CC? It doesnt take much common sense to see that investor sentiment changed at that time and the stock was going up from there. Dont give me the excuse there aren't any shares to short because there are plenty.
Quit your damn whining. If you cant handle losing you money on your SSH short than don't do it.
Everyone called out his BS on the Seeking Alpha comments section so I guess he figured he would come to the yahoo board to try and stir something up. All he is going to get is Ex asking him if he has ever talked to a cardiologist, yada, yada, yada. I just put bearcrusher on ignore myself.
I dont think so te_st5674. Seems pretty clear NPD to me. "has trouble keeping healthy relationships with others, easily hurt or rejected, appears unemotional, and exaggerating special achievements and talents
1)pretending to be a former CEO
2)pretending to go to the annual SSH shareholder meeting
3)Lying about formal stocks that he supposedly bought at the all time low
list goes on and on and on
We should just ask Ex himself- Do you think you have NPD or just an unkempt, idiosyncratic and eccentric person seeking attention??